Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study

Documenti analoghi

• Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
  di: Brendan Bender, et al.
  Pubblicazione: (2024)
• CAR‐DC combined with CAR‐T therapy for relapsed/refractory acute myeloid leukaemia: Research progress and future perspectives
  di: Rui Zhang, et al.
  Pubblicazione: (2025)
• Mutations of epigenetic genes and correlation with treatment response in peripheral T‐cell lymphoma
  di: Chong Wei, et al.
  Pubblicazione: (2024)
• Single‐cell analysis reveals cytotoxic and memory CD8 + T cells associated with prolonged survival in relapsed/refractory leukaemia patients after haplo+cord haematopoietic stem cell transplantation
  di: Hua Li, et al.
  Pubblicazione: (2026)
• Granulocyte colony‐stimulating factor induced T‐cell hyporesponsiveness via modulation of CD177 + S100A hi neutrophils in unexplained recurrent pregnancy loss
  di: Ping‐Fen Li, et al.
  Pubblicazione: (2025)